Business Description
Novacyt SA
NAICS : 325413
ISIN : FR0010397232
Compare
Compare
Traded in other countries / regions
ALNOV.FranceNCYT.UKNVYTF.USANYZ.Germany IPO Date
2018-08-29Description
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.51 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.46 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.69 | |||||
| Beneish M-Score | -1.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -65.2 | |||||
| 3-Year Book Growth Rate | -15.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.79 | |||||
| 9-Day RSI | 42.27 | |||||
| 14-Day RSI | 44.62 | |||||
| 6-1 Month Momentum % | -2.53 | |||||
| 12-1 Month Momentum % | -23.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.04 | |||||
| Quick Ratio | 3.82 | |||||
| Cash Ratio | 2.42 | |||||
| Days Inventory | 139.99 | |||||
| Days Sales Outstanding | 361.38 | |||||
| Days Payable | 60.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -35.87 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 154.81 | |||||
| Operating Margin % | -4.16 | |||||
| Net Margin % | -202.48 | |||||
| FCF Margin % | -159.5 | |||||
| ROE % | -42.71 | |||||
| ROA % | -30.98 | |||||
| ROIC % | -1.13 | |||||
| ROC (Joel Greenblatt) % | -161.06 | |||||
| ROCE % | -37.55 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.93 | |||||
| PB Ratio | 0.5 | |||||
| Price-to-Tangible-Book | 0.89 | |||||
| EV-to-EBIT | -0.41 | |||||
| EV-to-EBITDA | -0.54 | |||||
| EV-to-Revenue | 0.83 | |||||
| EV-to-FCF | -0.52 | |||||
| Price-to-Projected-FCF | 0.24 | |||||
| Price-to-Median-PS-Value | 3.09 | |||||
| Price-to-Net-Current-Asset-Value | 1.33 | |||||
| Price-to-Net-Cash | 8.39 | |||||
| Earnings Yield (Greenblatt) % | -243.9 | |||||
| FCF Yield % | -82.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novacyt SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 21.765 | ||
| EPS (TTM) (€) | -0.62 | ||
| Beta | 2.92 | ||
| Volatility % | 144.39 | ||
| 14-Day RSI | 44.62 | ||
| 14-Day ATR (€) | 0.024437 | ||
| 20-Day SMA (€) | 0.5821 | ||
| 12-1 Month Momentum % | -23.19 | ||
| 52-Week Range (€) | 0.475 - 1.388 | ||
| Shares Outstanding (Mil) | 70.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novacyt SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novacyt SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novacyt SA Frequently Asked Questions
What is Novacyt SA(FRA:NYZ)'s stock price today?
The current price of FRA:NYZ is €0.59. The 52 week high of FRA:NYZ is €1.39 and 52 week low is €0.48.
When is next earnings date of Novacyt SA(FRA:NYZ)?
The next earnings date of Novacyt SA(FRA:NYZ) is 2025-05-30 Est..
Does Novacyt SA(FRA:NYZ) pay dividends? If so, how much?
Novacyt SA(FRA:NYZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers